Rosenberger, G., Li, W., Turunen, M., He, J., Subramaniam, P. S., Pampou, S., Griffin, A. T., Karan, C., Kerwin, P., Murray, D., Honig, B., Liu, Y., & Califano, A. (2024). Network-based elucidation of colon cancer drug resistance mechanisms by phosphoproteomic time-series analysis. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47957-3

Dercle, L., Yang, M., Gönen, M., Flynn, J., Moskowitz, C. S., Connors, D. E., Yang, H., Lu, L., Reidy-Lagunes, D., Fojo, T., Karovic, S., Zhao, B., Schwartz, L. H., & Henick, B. S. (2023). Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials. European Radiology, 33(12), 9254–9261. https://doi.org/10.1007/s00330-023-09862-z

Elez, E., Kopetz, S., Tabernero, J., Bekaii-Saab, T., Taieb, J., Yoshino, T., Manji, G., Fernandez, K., Abbattista, A., Zhang, X., & Morris, V. K. (2024). SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC. Future Oncology, 20(11), 653–663. https://doi.org/10.2217/fon-2022-1249

Patel, R., Negassa, A., Tolu, S. S., Acuna-Villaorduna, A., & Goel, S. (2024). Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 23(1), 14-21.e1. https://doi.org/10.1016/j.clcc.2023.10.001

Flynn, J. R., Curry, M., Zhao, B., Yang, H., Dercle, L., Fojo, A. T., Connors, D. E., Schwartz, L. H., Gönen, M., & Moskowitz, C. S. (2023). Modeling Tumor Growth Using Partly Conditional Survival Models: A Case Study in Colorectal Cancer. JCO Clinical Cancer Informatics, 7. https://doi.org/10.1200/cci.22.00203

Chang, K. J., Kim, D. H., Lalani, T. K., Paroder, V., Pickhardt, P. J., Shaish, H., & Bates, D. D. B. (2023). Radiologic T staging of colon cancer: renewed interest for clinical practice. Abdominal Radiology, 48(9), 2874–2887. https://doi.org/10.1007/s00261-023-03904-2

Sugiura, K., Masuike, Y., Suzuki, K., Shin, A. E., Sakai, N., Matsubara, H., Otsuka, M., Sims, P. A., Lengner, C. J., & Rustgi, A. K. (2023). LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3. JCI Insight, 8(14). https://doi.org/10.1172/jci.insight.167310

Baldwin-Hunter, B. L., Rozenberg, F. D., Annavajhala, M. K., Park, H., DiMango, E. A., Keating, C. L., Uhlemann, A.-C., & Abrams, J. A. (2023). The gut microbiome, short chain fatty acids, and related metabolites in cystic fibrosis patients with and without colonic adenomas. Journal of Cystic Fibrosis, 22(4), 738–744. https://doi.org/10.1016/j.jcf.2023.01.013

Tan, S. X., Pumpalova, Y., Rogers, A. M., Bhatt, K., Herbst, C., Ruff, P., Neugut, A. I., & Hur, C. (2023). Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa. Cancer Medicine, 12(14), 15515–15529. Portico. https://doi.org/10.1002/cam4.6199

Abbass, M. A., & Church, J. (2023). Contemporary surgical management of colorectal cancer in Lynch syndrome. Journal of Surgical Oncology, 127(8), 1259–1263. Portico. https://doi.org/10.1002/jso.27318

Garcia, J. A., Chen, R., Xu, M., Comerford, S. A., Hammer, R. E., Melton, S. D., & Feagins, L. A. (2023). Acss2/HIF-2 signaling facilitates colon cancer growth and metastasis. PLOS ONE, 18(3), e0282223. https://doi.org/10.1371/journal.pone.0282223

Ma, W., Walker, M. M., Thuresson, M., Roelstraete, B., Sköldberg, F., Olén, O., Strate, L. L., Chan, A. T., & Ludvigsson, J. F. (2022). Cancer risk in patients with diverticular disease: A nationwide cohort study. JNCI: Journal of the National Cancer Institute, 115(1), 62–70. https://doi.org/10.1093/jnci/djac190

Soliman, S. S., Flanagan, J., Wang, Y. H., Stopper, P. B., Rolandelli, R. H., & Nemeth, Z. H. (2022). Comparison of Robotic and Laparoscopic Colectomies Using the 2019 ACS NSQIP Database. Southern Medical Journal, 115(12), 887–892. https://doi.org/10.14423/smj.0000000000001479

Reif de Paula, T., Gorroochurn, P., Haas, E. M., & Keller, D. S. (2022). A national evaluation of the predictors of compliance and survival from adjuvant chemotherapy in high-risk stage II colon cancer: A National Cancer Database (NCDB) analysis. Surgery, 172(3), 859–868. https://doi.org/10.1016/j.surg.2022.04.042

Hisamori, S., Mukohyama, J., Koul, S., Hayashi, T., Rothenberg, M. E., Maeda, M., Isobe, T., Valencia Salazar, L. E., Qian, X., Johnston, D. M., Qian, D., Lao, K., Asai, N., Kakeji, Y., Gennarino, V. A., Sahoo, D., Dalerba, P., & Shimono, Y. (2022). Upregulation of BMI1-suppressor miRNAs (miR-200c, miR-203) during terminal differentiation of colon epithelial cells. Journal of Gastroenterology, 57(6), 407–422. https://doi.org/10.1007/s00535-022-01865-9

Pumpalova, Y., Rogers, A. M., Tan, S. X., Herbst, C., Ruff, P., Neugut, A. I., & Hur, C. (2021). Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. JCO Global Oncology, 7, 1730–1741. https://doi.org/10.1200/go.21.00279